Linagliptin Intermediate Crystalline Forms B1 and B2 Process
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for producing linagliptin lack a safe, simple, and economical process for obtaining novel crystalline forms of linagliptin intermediates, which are crucial for enhancing the stability and bioavailability of the drug.
Innovation Solution
A novel process is developed to produce the novel crystalline form B1 and B2 Linagliptin intermediates, characterized by specific PXRD, DSC, and FT-IR patterns, and an anhydrous form A/B of Linagliptin, utilizing multi-step sequences involving reagents like potassium carbonate, DMSO, and MDC, with characterization techniques like Powder X-ray diffraction, Differential Scanning Calorimetry, and Fourier Transform Infrared spectroscopy.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Ease of manufacture
If current methods for producing linagliptin are used, then production can be maintained, but the process lacks safety, simplicity, and economy in obtaining novel crystalline forms of linagliptin intermediates
Solution Approach 1:
The patent applies parameter changes by modifying reaction conditions including temperature ranges (0-5°C, 20-25°C, 40-45°C), pH levels (pH 2-4 for stabilization), solvent systems (acetonitrile, methanol, water mixtures), and crystallization parameters to obtain novel crystalline forms B1 and B2 of linagliptin intermediate with specific PXRD patterns and improved safety profile
Solution Approach 2:
The patent uses intermediary substances including potassium carbonate as a base catalyst, DMSO as solvent, and specific buffer systems (acetate buffer pH 4.0, citrate buffer pH 3.0) to mediate the reaction between compounds of formula I and II, enabling safe and controlled formation of the desired crystalline intermediates
2Ease of manufacture
If current methods for producing linagliptin are used, then production can be maintained, but the process lacks economy in obtaining novel crystalline forms of linagliptin intermediates
Solution Approach 1:
The patent optimizes economic parameters by using cost-effective reagents (potassium carbonate instead of more expensive bases), efficient solvent systems (acetonitrile-methanol-water mixtures), and controlled crystallization conditions (temperature gradients from 40-45°C to 0-5°C) that yield stable novel crystalline forms B1 and B2 with defined PXRD patterns while reducing production costs
Solution Approach 2:
The patent exploits phase transitions during crystallization by controlling temperature changes (cooling from 40-45°C to 0-5°C), solvent evaporation rates, and anti-solvent addition to induce formation of stable novel crystalline forms B1 and B2 with specific polymorphic structures confirmed by PXRD, DSC, and FT-IR characterization
3Productivity
If non-crystalline or unstable crystalline forms of linagliptin intermediate are used, then production simplicity is maintained, but bioavailability and stability of the drug are reduced
Solution Approach 1:
The patent enhances bioavailability by producing stable novel crystalline forms B1 and B2 of linagliptin intermediate with specific physical and chemical properties through controlled parameter changes including pH adjustment (pH 2-4), temperature control (0-5°C for final crystallization), solvent composition (acetonitrile-methanol-water ratios), and crystallization rate control to ensure high purity and defined crystal structure
Solution Approach 2:
The patent applies preliminary action by pre-cooling reaction mixtures to 0-5°C before adding anti-solvents (water or methanol), pre-adjusting pH to optimal ranges (pH 2-4), and pre-mixing solvent systems in specific ratios to ensure controlled and reproducible formation of stable novel crystalline forms B1 and B2 with improved bioavailability characteristics
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The process provides a stable and pure crystalline form of linagliptin, improving its bioavailability and manufacturability, and expands the options for pharmaceutical dosage forms with enhanced performance profiles.
Implementation Method 1
The reaction of compounds of formula I and II in the presence of base catalysts such as potassium carbonate
Implementation Method 2
in solvents such as DMSO
Implementation Method 3
novel crystalline form B1 and B2 Linagliptin intermediates
Implementation Method 4
in solvents such as MDC
Data Source
AI summary
The present invention provides novel crystalline forms B1 & B2 of linagliptin intermediate of structural formula V and methods for production of novel crystalline form of linagliptin intermediate represented by the following structural formula V.